Bullish
Eli Lilly's oncology revenue rises 11% in H1 2026, bolstering growth beyond GLP-1 drugs.
Eli Lilly's oncology division reported an 11% revenue increase to $4.84 billion in the first half of 2026, driven by strong sales of Verzenio and Jaypirca. This growth underscores the company's expanding presence in cancer treatments, complementing its established GLP-1 drug portfolio.
Key points
- Oncology revenue up 11% to $4.84 billion in H1 2026.
- Jaypirca sales surged 66% to $357 million, expanding in CLL and mantle cell lymphoma.
- Pipeline acquisitions enhance presence in hematologic cancers.
Sources
AI-generated from public news sources. Not financial advice.
